

January 12, 2016



BioSig Technologies to Present at NobleCon12

Minneapolis, MN, Jan. 12, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) today announced that its President & Chief Executive Officer, Greg Cash and VP Corporate Finance & Investor Relations, Brian McLaughlin will be participating at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference to be held January 17-20, 2016 in South Florida.

Event: NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference

Date: Monday, January 18

Time: 4:00 PM EST in Room 1

BioSig President & Chief Executive Officer, Greg Cash will deliver the Company's corporate presentation and discuss recent business highlights including milestones achieved in 2015 as well as objectives for the next twelve months and beyond. To arrange a meeting with management, please email Brian McLaughlin at bmclaughlin@biosigtech.com.

After the Conference on January 22, 2016, a high-definition video webcast of BioSig's presentation and a copy of the presentation materials will be available on the Company's website www.biosigtech.com or as part of a complete catalog of presentations available at Noble Financial websites: www.noblefcm.com or www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

About BioSig Technologies

BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the \$3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.

PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound

annual growth rate, from \$2.5 billion in 2012 to \$5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).

BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.

1. Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
2. HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.

About Noble Financial Capital Markets

Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB. www.noblefcm.com

Contact:

Investor Relations:

Brian McLaughlin

BioSig Technologies, Inc.

bmclaughlin@biosigtech.com

917-370-9817



Source: BioSig Technologies, Inc.